12 assets in Carcinoid Tumor

Therapeutic assets addressing Carcinoid Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Oxodotreotide Carcinoid Tumor	RayzeBio, Inc.	P3	BB (64)
Paltusotine Carcinoid Tumor	Crinetics Pharmaceuticals Inc.	P3	BB (64)
Everolimus Carcinoid Tumor	RayzeBio, Inc.	P3	B (62)
Lanreotide Carcinoid Tumor	RayzeBio, Inc.	P3	B (60)
L-Cysteinamide, D-Phenylalanyl-L-Cysteinyl-L-Phenylalanyl-D-Tryptophyl-L-Lysyl-L-Threonyl-N-(2-Hydroxy-1-(Hydroxymethyl)Propyl)-, Cyclic (2->7)-Disulfide, (R-(R,R))- Carcinoid Tumor	RayzeBio, Inc.	P3	B (60)
Edotreotide Carcinoid Tumor	British Columbia Cancer Agency	P2	B (59)
Cabozantinib Carcinoid Tumor	Fox Chase Cancer Center	P2	B (57)
Domvanalimab Carcinoid Tumor	Hospices Civils de Lyon	P2	CCC (53)
Nivolumab Carcinoid Tumor	Fox Chase Cancer Center	P2	CCC (53)
Pembrolizumab Carcinoid Tumor	Merck Sharp & Dohme LLC	P2	CCC (53)
Zimberelimab Carcinoid Tumor	Hospices Civils de Lyon	P2	CCC (53)
ryz401 Carcinoid Tumor	RayzeBio, Inc.	P1	CC (43)